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Clinical efficacy, utilities and transition probabilities were derived from published 
studies. Resource costs were estimated from 656 individual patient level data from 
Adelphi 2012 UK patient dataset, using Irish costs, where possible. Time horizon 
was 20 years and patients were followed until death if it occurred earlier. Costs 
and outcomes were discounted at 4%. Both one-way and probabilistic sensitivity 
analyses were conducted.. RESULTS: The incremental cost-effectiveness ratio for 
LCIG vs. SOC was € 41,114/QALY (total costs LCIG vs. SoC are € 537,276 vs. € 465,716 
and QALYs are 4.72 vs. 2.98). LCIG is cost-effective at a payer threshold of € 45,000. 
The model is most sensitive to health state costs. CONCLUSIONS: LCIG is a cost-
effective option in treating APD patients in Ireland.
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OBJECTIVES: To compare the cost-effectiveness of current disease modifying thera-
pies (DMT) for patients with relapsing-remitting multiple sclerosis (RRMS) in the 
US. METHODS: An economic model was created to predict the course of patients 
with RRMS following initiation of a DMT. Natalizumab (NAT), dimethyl fumarate 
(DMF), and peginterferon beta-1a (PEG), were compared with fingolimod (FIN), glati-
ramer acetate (GA, 40 milligrams thrice weekly), and interferon beta-1a (INT, 44 
micrograms thrice weekly), respectively. The Markov state transition cohort model 
predicted disease progression across RRMS Expanded Disability Status Scale [EDSS] 
states and for secondary-progressive (SPMS) EDSS states in 3-month cycles over a 
10-year time horizon. The patient cohort was at risk of death, relapse, or discontinu-
ation (due to reaching EDSS level 7, or following DMT-specific rates) in each cycle. 
Outcome measures were relapses, relapse-free time, MS progression, and progres-
sion and clinical disease activity-free years. Costs included drug, administration, 
monitoring, relapse, and EDSS state costs. Incremental cost-effectiveness ratios 
(ICERs) were estimated for each of the outcome measures. RESULTS: Costs ranged 
from $477,158 (DMF) to $526,667 (INT). NAT, DMF, and PEG were less expensive with 
equal, or better, outcomes. NAT and DMF were dominant (less costly and more 
effective) compared to FIN and GA, respectively, for all ICERs. PEG dominated INT 
on progression and clinical disease activity outcomes. Comparable relapse-related 
outcomes cost more than $30,000 with INT compared to PEG. Variability in drug 
costs and parameters that affected drug cost accrual (eg, discontinuation rates 
and the decision to drop out after SPMS conversion) had a considerable impact on 
ICERs. CONCLUSIONS: Results from this analysis suggest that the NAT, DMF and 
PEG are cost-effective DMT choices compared to FIN, GA, and INT, respectively. The 
actual impact to a particular plan will vary based on drug pricing and other factors 
affecting drug cost accrual.
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OBJECTIVES: To analyze cost effectiveness of amitriptyline and propranolol in the 
management of migraine METHODS: A total of 60 patients with migraine were 
enrolled, into the Prospective, observational, exploratory study based on the inclu-
sion and exclusion criteria. Migraine headache frequency, duration and used of over 
the counter drugs per month migraine headache pain score and headache impact 
test score were assessed and recorded at baseline by using a suitably designed ques-
tionnaire and headache impact test questionnaire. The patients were given either 
amitriptyline or propranolol . After the completion of one month of drug therapy 
score of patients were measured using the same questionnaire and in addition cost 
of prescription drugs and over the counter drugs were calculated.The effectiveness 
of treatment on patients was evaluated by comparing the mean scores before and 
after treatment by applying paired sampled T- test and independent sample test to 
compare means between the two treatment groups. Cost effectiveness analysis was 
done in terms of reduction of headache frequency per month before and after the 
treatment . RESULTS: The result showed that to prevent single migraine headache 
patient under amitriptyline group has to pay NRs.8.897 on the drugs (amitriptyline 
and analgesic)where patient under Propranolol group has to pay NRs.30.11 on the 
drugs (propranolol and analgesic) to prevent single migraine headache. In addi-
tion the study suggests using either amitriptyline or propranolol for treatment of 
migraine headache is same in terms of reduction of headache frequency and in 
terms of reduction of headache duration. However amitriptyline was found supe-
rior to propranolol in terms of reduction of headache impact test score and used of 
over the counter drugs. But propranolol was found to significantly lower headache 
pain score compare to amitriptyline. CONCLUSIONS: Amitriptyline is the most cost 
effective option when compared to propranolol in migraine.
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OBJECTIVES: Compare the cost-efectiveness (CE) of levodopa, pramipexole, rasagil-
ine and selegiline in patients with early Parkinson’s disease from the perspective 
of National Institute of Neurology and Neurosurgery (NINN) in Mexico. METHODS: 
We developed a CE model, that linked Unified Parkinson’s Disease Rating Scale 
(UPDRS) Parts II (activities of daily life) and III (motor) scores to disease progres-
sion and direct costs (drugs, medical appointments, adverse events, and labora-
tory studies), which were obtained of clinical records and unit cost of NINN. Data 
used in the model were obtained from clinical trials and we developed an indirect 
patients without CM ($1,756). There were more CM patients with accompanying pain 
at all levels (mild: 19.53% vs. 0.16%; moderate: 13.10% vs. 0.10%; severe: 16.20% vs. 
0.12%; all p< 0.0001). CONCLUSIONS: CM patients in the VHA population had sub-
stantial health care resource utilization, incurred higher costs and suffered worse 
pain compared to those without the disease.
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OBJECTIVES: To examine the health care resource utilizations and costs among 
migraine patients in the U.S. Medicaid population. METHODS: Migraine patients 
were identified (International Classification of Disease, 9th Revision, Clinical 
Modification [ICD-9-CM] diagnosis code 346) using Medicaid data from January 01, 
2009 through December 31, 2009. The first diagnosis date was designated as the 
index date, and patients were required to have at least a 1-year baseline (pre-index 
date) and 1-year follow-up (post-index date) period. A comparison cohort was cre-
ated for patients without a migraine diagnosis during the study period, using 1:1 
propensity score matching to control for age, region, gender and baseline Charlson 
Comorbidity Index score. The comparison cohort’s index date was chosen at ran-
dom to minimize selection bias. Patients in both cohorts were required to be age 
≥ 18 years and have continuous medical and pharmacy benefits 1-year pre- and 
post-index date. Study outcomes (health care resource utilizations and costs) were 
compared between the migraine and comparison cohorts. RESULTS: After applying 
PSM, 380,751 patients were assigned to each cohort, and baseline characteristics 
were well-balanced. A higher percentage of patients with migraines had inpatient 
stays (21.53% vs. 11.00%, p< 0.0001), other therapy (99.88% vs. 65.78%, p< 0.001) and 
pharmacy visit claims (90.52% vs. 48.35%, p< 0.0001), compared to those without a 
migraine diagnosis. The patients in the migraine cohort also incurred significantly 
higher other therapy ($4,111 vs. $2,312, p< 0.0001) and pharmacy visit costs ($1,074 
vs. $512, p< 0.0001) than those in the comparison cohort. CONCLUSIONS: Migraine 
patients incurred significantly higher costs and had higher health care resource 
utilizations than those without migraines.
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OBJECTIVES: Parkinson’s disease (PD) is a progressive disease associated with 
substantial economic and societal burden. Immediate-release (IR) carbidopa-levo-
dopa (CD-LD) is the gold standard in treatment for advanced PD patients. However, 
effectiveness of IR CD-LD diminishes with long-term treatment and is associated 
with increased “off” time (re-emergence of PD symptoms) and the advent of motor 
complications. CD-LD plus entacapone (CL+E) has produced some clinical improve-
ment over IR CD-LD alone. IPX066 is an extended-release oral formulation of CD-LD 
designed to address some of the limitations of IR CD-LD by rapidly attaining and 
maintaining therapeutic LD concentrations for a prolonged duration. The aim of 
the study was to evaluate the comparative cost-effectiveness of IPX066 against 
CL+E. METHODS: A Markov model was developed comparing IPX066 with branded 
and generic CL+E in the US market. Health states included ≤ 25% “off” time, > 25% 
“off” time, and dead. The model simulated a hypothetical patient’s progression over 
a 5-year period through these health states, with a 6-month Markov cycle length. 
Outcomes evaluated were total direct costs, quality-adjusted life years (QALYs), 
and incremental cost-effectiveness ratios (ICER). Dosing and efficacy data from 
a Phase 3 study comparing IPX066 and CL+E, average wholesale acquisition drug 
costs (RedBook), and published literature were utilized for this evaluation. Non-2014 
costs were inflated to reflect the 2014 value using the medical component of the 
Consumer Price Index. The discount rate employed was 3%. RESULTS: IPX066 was 
dominant over both branded and generic CL+E therapies, with ICERs of (-$166,044) 
and (-$75,920), respectively. On average, patients who received IPX066 experienced 
a 5.1% increase in QALYs (2.90) compared with patients who did not receive IPX066 
(2.76). IPX066 dominated the other two therapies throughout multiple sensitivity 
analyses, driven largely by improved effectiveness of IPX066. CONCLUSIONS: IPX066 
is likely to be a cost-effective therapy in patients with advanced PD.
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BACkgROUND: Parkinson’s disease (PD) is an incurable, progressive neurological 
disease, with primary symptoms impacting movement, walking and posture; that 
eventually become severely disabling. Advanced PD (APD) has a significant impact 
on Quality of Life (QoL) for patients, their carer’s/families. Levodopa/Carbidopa 
intestinal gel (LCIG) is indicated for the treatment of advanced levodopa-responsive 
Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when 
available combinations of Parkinson medications have not given satisfactory results. 
There are no published studies reporting the economic value of LCIG in treatment 
of patients with APD in Ireland. OBJECTIVES: Determine the cost-effectiveness of 
LCIG compared with Standard of care (SoC) for the treatment of APD patients in 
Ireland METHODS: A deterministic Markov model was used to evaluate LCIG vs. 
SoC in APD patients with severe motor fluctuations from an Irish health care per-
spective. The model simulated a cohort of 100 patients and redistributed them into 
disease-specific health states. Health states were defined by Hoehn & Yahr (H&Y) 
scale combined with amount of time in OFF-time. SoC comprised of standard oral 
therapy +/- sub-cutaneous apomorphine infusion and standard follow up visits. 
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NUEDEXTA (dextromethorphan/quinidine) is the only FDA and EMA approved PBA 
treatment. The primary objective of this analysis is to evaluate healthcare utili-
zation and costs in PBA patients before and after dextromethorphan/quinidine 
treatment. For this analysis type of service unit utilized and overall utilization 
are both functions of cost. METHODS: Retrospective analysis using anonymized 
patient level data from a large national health insurer. Claims data (both commercial 
and Medicare) were assessed for each eligible patient, for an observation period 
including the 12 months before (baseline) and 12 months after (follow-up) the Index 
Date, defined as the first prescription fill date for dextromethorphan/quinidine. 
Eligibility requirements were an Index Date between January 1, 2007 through August 
31, 2013, and continuous insurance eligibility for the entire 24 month observation 
period . RESULTS: A cohort of 1245 patients treated with dextromethorphan/qui-
nidine was identified; 488 of whom met eligibility requirements. Mean healthcare 
costs, primarily driven by utilization, were reduced in the 12 months following 
dextromethorphan/quinidine use compared with the 12 months pretreatment, 
including reduction of inpatient costs (27%), emergency room visits (19%), stroke-
related postcare (73%) and ancillary costs (2%). Pre-index costs were not reflective 
of costs related to acute stroke treatment in stroke patients, as no patient had a 
stroke during the 12-month pre-index (baseline) period. Despite the added prescrip-
tion cost of dextromethorphan/quinidine, the overall weighted mean cost reduc-
tion was 5%. CONCLUSIONS: Patients treated with dextromethorphan/quinidine 
(NUEDEXTA) showed a decrease in healthcare utilization and costs compared to 
the pre-index period.
PND39
healTh Care resourCe uTilizaTioN before aND afTer NaTalizuMab 
iNiTiaTioN aMoNg MulTiPle sClerosis PaTieNTs iN gerMaNy
Watson C1, Prosser C2, Braun S2, Landsman-Blumberg P3, Naoshy S1
1Biogen Idec, Cambridge, MA, USA, 2Xcenda GmbH, Hannover, Germany, 3Xcenda LLC, Palm 
Harbor, FL, USA
OBJECTIVES: To evaluate multiple sclerosis (MS)-related health care resource 
utilization and costs prior to and after initiating natalizumab in 
Germany. METHODS: A retrospective claims database analysis was conducted 
using the Health Risk Institute research database to identify MS patients ini-
tiating natalizumab (index date) between 1/1/2009 and 12/31/2012. Patients 
had 24 months of continuous enrollment (12 months before [pre-period] and 
12 months after [post-period] the index date) and at least one natalizumab pre-
scription in the 4th quarter after the index date. Furthermore, patients with and 
without other disease-modifying treatment (DMT) during the pre-period were 
examined. Patient characteristics, MS-related inpatient stays, and corticos-
teroid use were compared in both periods using paired statistical tests, where 
appropriate. RESULTS: The study included 193 patients, mean age 37.1 years 
(standard deviation 10.2), 64.8% female. The majority (75.1%) used a DMT dur-
ing the pre-period. After initiating natalizumab, there was a significant reduc-
tion in the percentage of patients with MS-related inpatient stays (49.7% 
versus 14.0%, P< 0.001), MS-related inpatient costs (mean € 3,759 versus 
€ 815, P< 0.001), and length of stay (mean 7.0 days versus 2.7 days, P< 0.001) 
compared to the pre-period. In patients without pre-period DMTs, there was a 
significant reduction in the percentage of patients with MS-related inpatient stays 
(–77.3% P< 0.001) and costs (-€ 3052.0; P< 0.001) and patients with DMTs in the pre-
period showed similar significant reductions (–70.2% and –€ 2908.2, respectively, 
P< 0.001 for both). Compared to the pre-period, there were significant reductions 
in corticosteroid use for all natalizumab initiators (–62.3%, P< 0.001), which cor-
responded to a mean corticosteroid cost-per-patient reduction of –€ 290.75 across 
all natalizumab users (P< 0.001). CONCLUSIONS: In Germany, the initiation of 
natalizumab was associated with significant decreases in MS-related inpatient 
stays, and corticosteroid use with corresponding decreases in the average length of 
stay and costs among natalizumab users with and without DMTs in the prior year.
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OBJECTIVES: sIBM is a progressive idiopathic inflammatory myopathy characterized 
by atrophy and weakness of proximal and distal muscle groups; knee extensors and 
wrist/finger flexors and dysphagic processes are frequently involved. Progressive 
weakness results in loss of independence and need for assistive devices and sup-
portive care. The progressive nature of sIBM leads to increasing medical expenses, 
many of which are not covered by third-party payers, making quantification difficult 
using existing databases. SMART-sIBM, a self-report tool, was developed to better 
characterize out-of-pocket expenses and non-reimbursable items not captured by 
health care systems. METHODS: SMART-sIBM was developed based on in-depth 
interview data from 20 sIBM patients, review of existing resource-use measures, 
and input from clinical experts (n= 9). SMART-sIBM captures resource utilization 
and costs of sIBM over a 6-month, retrospective recall period, including out-of-
pocket costs and third-party payer expenses. A cross-sectional study (n= 102 sIBM 
patients) was conducted in the US to gather preliminary resource utilization and 
patient financial data. Draft versions were reviewed by clinical experts and patients 
independently, and were refined before use in the cross-sectional study. RESULTS: 
Patients had a mean age of 66 years, disease duration of 1-18 years, and varied physi-
cal limitations. All patients reported need for frequent health care visits, and 80% 
indicated need for house/vehicle modifications and purchase of assistive equipment 
to accommodate sIBM-related disabilities. Nearly one-third of patients required 
paid help with household tasks, while more than one-half relied on help from 
unpaid caregivers (e.g., spouse, friend). Nearly half (45%) reported changes in job 
status because of sIBM-related functional limitations. CONCLUSIONS: Results of 
comparison to evaluate the efficacy and safety, with the study of Jiao and cols., an 
hypothetical cohort were placed in accordance with this efficacy and the Hoehn 
and Yahr states, an analysis of incremental cost-effectiveness ratio (ICER) was 
performed. We used a markov model to estimate the CE and performed sensitivity 
analyses and varying disease progression parameters and costs. The outcome of 
effectiveness was life years gained. RESULTS: For patients with early PD in mono-
therapy, treatment with levodopa had lower costs and more effectiveness than 
pramipexole, rasagiline and selegiline treatments. With a time horizon of 5 years, 
levodopa was 5.04 life years gained and cost $236,750.52, the cost of selegiline 
was $247,094.21 with 4.1 life years gained, pramipexol had a cost of $247,420.46 
with 4.1 life years gained and finally rasagilina $254,006.56 with 3.17 life years 
gained, all values of ICER were less than one GDP per capital. This results showed 
that levodopa was the dominant alternative. The sensitivity analyses confirm the 
results. CONCLUSIONS: Findings of this study indicate that levodopa provides 
the major effectiveness and the lower cost compared to pramipexole, rasagiline 
and selegiline as first treatment option in patients with early Parkinson disease 
(measured by UPDRS) in monotherapy.
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OBJECTIVES: Lisdexamfetamine dimesylate (LDX) demonstrated efficacy in terms 
of reduced binge eating days per week in adults (18-55 years old) with binge eating 
disorder (BED) in 2 randomized control trials (RCTs). This study examined the cost-
effectiveness of LDX compared to placebo for the treatment of adult BED patients 
in the United States (U.S.). METHODS: A decision-analytic Markov cohort model 
comparing LDX to placebo was developed using 1-week cycles and a 52-week time 
horizon. Based upon the 5th Edition of the Diagnostic and Statistical Manual of 
Mental Disorders criteria of BED, the model comprised the following health states: 
non-symptomatic BED, sub-threshold BED, mild BED, moderate BED and severe 
and extreme BED. Model parameter estimates including transition probabilities, 
utility values and resource utilization were obtained from RCTs, a survey, and lit-
erature. All cost data were inflated to 2013. The primary outcome was incremental 
cost-effectiveness ratio (ICER). The base case analysis assumed a 12-week course 
of treatment, based upon RCTs’ treatment duration. RESULTS: Patients on LDX 
therapy gained 0.0064 quality-adjusted life years (QALY) compared to patients on 
the NPT arm, while the average total cost was $175 higher for LDX therapy. LDX 
therapy yielded the ICER of $27,512 per QALY gained vs placebo and was shown to 
be cost-effective given a willingness-to-pay threshold of $50,000. CONCLUSIONS: 
Treatment of BED with LDX showed an increase in QALYs at an acceptable cost and 
considered cost-effective at the commonly used willingness-to-pay thresholds in 
the U.S. There is a need to generate additional scientific evidence supporting long-
term benefits of LDX therapy for BED.
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OBJECTIVES: To evaluate the cost-effectiveness of glatiramer acetate (COPAXONE®) 
for relapsing-remitting multiple sclerosis (RRMS) compared to interferons-β (IFNs) 
in scenarios with and without routine testing for the presence of neutralizing anti-
bodies (NAbs) in people receiving IFNs. NAbs reduce the therapeutic benefits of 
interferons-β (IFNs). Glatiramer acetate does not develop NAbs. METHODS: The 
impact of NAb testing was evaluated using a Markov model previously developed 
for the Netherlands. The model followed patients over 50 years through 21 health 
states: Expanded Disability Status Scale (EDSS) 0-9 for patients with RRMS and 
secondary progressive multiple sclerosis, respectively, and death (EDSS 10). Baseline 
demographics, transition probabilities, treatment-specific relative risks, and utility 
values were obtained from published literature. Health resource use was based on 
the products’ Summary of Product Characteristics and treatment guidelines. 2014 
unit costs were based on national tariffs and published data from the Netherlands. 
The analysis was conducted from the societal perspective. RESULTS: In the scenario 
without routine NAb testing total treatment costs of glatiramer acetate were lower 
versus most IFNs. It also resulted in higher number of quality-adjusted life-years 
compared to all IFNs as some IFN patients received ineffective treatment. In the 
scenario with routine NAb testing total treatment costs of all IFNs were higher 
than in the other scenario and higher than glatiramer acetate due to switching to 
more expensive treatments than first-line injectables. In both scenarios glatiramer 
acetate was dominant against most IFNs. CONCLUSIONS: In both scenarios where 
NAb testing is routine practice or not, glatiramer acetate is less costly and more 
effective versus interferon-β -1a 44mcg, 30mcg, and 22mcg for RRMS.
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OBJECTIVES: Pseudobulbar affect (PBA) is an underdiagnosed condition character-
ized by sudden, involuntary episodes of crying and/or laughing in patients with 
traumatic brain injury or certain neurologic diseases, including multiple sclerosis, 
amyotrophic lateral sclerosis, stroke, Alzheimer’s disease, and others. Studies sug-
gest that PBA symptoms are associated with added healthcare utilization and costs. 
